<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0017">
 <label>17.</label>
 <mixed-citation publication-type="journal">
  <string-name>
   <surname>Zeuzem</surname>
   <given-names>S</given-names>
  </string-name>, 
  <string-name>
   <surname>Foster</surname>
   <given-names>GR</given-names>
  </string-name>, 
  <string-name>
   <surname>Wang</surname>
   <given-names>S</given-names>
  </string-name>, et al. 
  <article-title>Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection</article-title>. 
  <source>
   <italic toggle="yes">N Engl J Med</italic>
  </source>. 
  <year>2018</year>;
  <volume>378</volume>(
  <issue>4</issue>):
  <fpage>354</fpage>â€“
  <lpage>369</lpage>. doi:
  <pub-id pub-id-type="doi">10.1056/NEJMoa1702417</pub-id>
  <pub-id pub-id-type="pmid">29365309</pub-id>
 </mixed-citation>
</ref>
